Loading stock data…
LIVN
$77.17+2.37 (+3.17%)
After Hours$77.18+0.01 (+0.01%)· Last close Jun 9
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LivaNova PLC in the Healthcare sector is trading at $77.17. Wall Street consensus targets $80.60 (10 analysts), implying a +4.4% move over the next 12 months. The stock is currently near its 52-week high of $77.78, remaining 24.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$77.17
Potential Downside
0%
Whystock Fair Value$77.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$80.60+4.4%
Range$67.00 – $95.00
Fundamentals
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switz...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.85%
Volume
Today's trading volume
658,613
Recent News
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why LivaNova (LIVN) Is Up 18.0% After Boosting 2026 Outlook And Winning Aura6000 FDA Approval
LivaNova PLC previously reported that first-quarter 2026 sales rose to US$362.26 million from US$316.86 million a year earlier, with net income improving to US$22.29 million from a very large net loss and basic earnings per share from continuing operations turning positive at US$0.41. Alongside beating adjusted earnings expectations and lifting full-year 2026 revenue and EPS guidance, LivaNova secured FDA premarket approval for its aura6000 System to treat moderate to severe obstructive...
LivaNova (LIVN) Q1 2025 Earnings Transcript
Briana Gotlin: Thank you, and welcome to our conference call and webcast discussing LivaNova's financial results for the first quarter of 2025. Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and Member of the Board of Directors; Alex Shvartsburg, our Chief Financial Officer; Ahmet Tezel, our Chief Innovation Officer; Stephanie Bolton, President of Global Epilepsy; and Zach Glazier, Director of Investor Relations.
LivaNova PLC Q1 2026 Earnings Call Summary
Moby summary of LivaNova PLC's Q1 2026 earnings call
LivaNova Q1 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported first-quarter 2026 results that management said reflected “durable performance” across its cardiopulmonary and epilepsy businesses, while also highlighting recent regulatory and clinical milestones that it believes position the company for entry into the obstructive s